456 related articles for article (PubMed ID: 26749342)
1. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
2. Development of a risk score for QTc-prolongation: the RISQ-PATH study.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2017 Apr; 39(2):424-432. PubMed ID: 28281228
[TBL] [Abstract][Full Text] [Related]
3. Risk Management of Hospitalized Psychiatric Patients Taking Multiple QTc-Prolonging Drugs.
Vandael E; Vandenberk B; Willems R; Reyntens J; Vandenberghe J; Foulon V
J Clin Psychopharmacol; 2017 Oct; 37(5):540-545. PubMed ID: 28817488
[TBL] [Abstract][Full Text] [Related]
4. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
Greco KE; Tune LE; Brown FW; Van Horn WA
J Clin Psychiatry; 2005 Jul; 66(7):928-9. PubMed ID: 16013910
[TBL] [Abstract][Full Text] [Related]
6. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and determinants of QT interval prolongation in medical inpatients.
Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
[TBL] [Abstract][Full Text] [Related]
8. Incidences, risk factors, and clinical correlates of severe QT prolongation after the use of quetiapine or haloperidol.
Wang CL; Wu VC; Lee CH; Wu CL; Chen HM; Huang YT; Chang SH
Heart Rhythm; 2024 Mar; 21(3):321-328. PubMed ID: 38231170
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Torsade de Pointes in a tertiary hospital population.
Vandael E; Vandenberk B; Vandenberghe J; Pincé H; Willems R; Foulon V
Int J Cardiol; 2017 Sep; 243():511-515. PubMed ID: 28576628
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drugs and QT interval prolongation.
Zareba W; Lin DA
Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
Glassman AH; Bigger JT
Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
[TBL] [Abstract][Full Text] [Related]
12. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
14. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol-induced torsade de pointes.
O'Brien JM; Rockwood RP; Suh KI
Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
[TBL] [Abstract][Full Text] [Related]
16. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
Jardin CG; Putney D; Michaud S
Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
[TBL] [Abstract][Full Text] [Related]
17. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Overholser BR; Mourad NA; Trujillo TN; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):381-90. PubMed ID: 24803473
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
Izumi-Nakaseko H; Nakamura Y; Cao X; Wada T; Ando K; Sugiyama A
Cardiovasc Toxicol; 2017 Jul; 17(3):319-325. PubMed ID: 27738880
[TBL] [Abstract][Full Text] [Related]
20. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
